AstraZenenca liver cancer combination treatment approved by FDA

AstraZeneca said its Imjudo drug, in combination with Imfinzi, hadbeen approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer, the company said on Monday.
The approval by the US Food and Drug Administration (FDA) was based on positive results from the HIMALAYA Phase III trial. In this trial, patients treated with the combination of Imjudo and Imfinzi experienced a 22% reduction in the risk of death versus Bayer’s sorafenib.